Chiesi Farmaceutici SpA
International pharmaceutical group with R&D, clinical development, manufacturing and global commercial operations. Public-facing capabilities include clinical trial conduct and transparency, pharmacovigilance and medical information, partnering and licensing (including open innovation and digital health), and site-based production with programs for supply continuity and sustainability.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Services
Support for collaboration, licensing and alliance activities across therapeutic areas.
Conduct and public reporting of clinical research and facilitation of data sharing according to transparency policies.
Collection and management of adverse event reports and pharmacovigilance communications for marketed products.
Site-based manufacture and distribution of pharmaceutical products with programs to maintain supply continuity.
Programs to engage external innovators and digital health partners through dedicated initiatives.
Support for collaboration, licensing and alliance activities across therapeutic areas.
Conduct and public reporting of clinical research and facilitation of data sharing according to transparency policies.
Collection and management of adverse event reports and pharmacovigilance communications for marketed products.
Site-based manufacture and distribution of pharmaceutical products with programs to maintain supply continuity.
Programs to engage external innovators and digital health partners through dedicated initiatives.
Expertise Areas
- Clinical trial management
- Pharmacovigilance
- Pharmaceutical manufacturing and CMC
- Regulatory compliance and quality assurance
Key Technologies
- Clinical trial data sharing platforms
- Pharmacovigilance IT systems
- Digital health platforms
- Commercial pharmaceutical manufacturing processes
News & Updates
Announcement of the decision to stop all clinical studies related to a development program referred to as Tanimilast.
Press release announcing an exclusive license agreement with an external partner for treatments in lysosomal diseases (press release referenced with location and date).
Announcement of the decision to stop all clinical studies related to a development program referred to as Tanimilast.
Press release announcing an exclusive license agreement with an external partner for treatments in lysosomal diseases (press release referenced with location and date).